SOURCE: AtCor Medical Holdings Ltd.

October 22, 2007 08:30 ET

AtCor to Present at Rodman & Renshaw 9th Annual Healthcare Conference

SYDNEY, AUSTRALIA and LISLE, IL--(Marketwire - October 22, 2007) - AtCor Medical Holdings Limited (ASX: ACG), the developer and marketer of the SphygmoCor® system, which non-invasively measures central blood pressures, today announced that the Company is scheduled to present at the Rodman & Renshaw 9th Annual Global Healthcare Conference, on November 5-7, in New York City.

Duncan Ross, AtCor Medical's Chief Executive Officer, will give a presentation on November 7, at 10:50 a.m. ET on the Company's patented and FDA-cleared SphygmoCor® technology, which provides non-invasive assessment of central blood pressure and indices of arterial stiffness. The presentation will be followed by a question and answer session and a live webcast may be accessed at the Company's website, www.atcormedical.com, or at http://wsw.com/webcast/rrshq12/acg.au.

A replay of the presentation will be archived for 90 days after the conference, at the same locations. For more information about the Rodman & Renshaw 9th Annual Healthcare Conference, please visit Rodman & Renshaw's website at www.rodmanandrenshaw.com.

AtCor Medical management will be available for meetings in New York on November 6-7.

Major independent clinical studies using SphygmoCor® have shown that central pressure is a superior predictor of cardiovascular events and that it reveals important drug effects that cannot be detected with traditional cuff blood pressure measurements.

Nine of the top ten leading hospitals in the US News & World Report's 2007 edition of "America's Best Hospitals" (published October 16, 2007 at http://health.usnews.com/usnews/health/best-hospitals/honorroll.htm) have adopted SphygmoCor® non-invasive central blood pressure measurement. In July, the Company announced that it had signed agreements with three leading international pharmaceutical companies to supply SphygmoCor® systems and clinical trial support services for new and ongoing drug trials in Europe and the United States.

Heart disease is the leading cause of death in the U.S. AtCor's SphygmoCor® system is the only FDA-cleared, non-invasive method to measure central pressures. Central blood pressure comprises the pressure exerted by the heart's contraction, plus the added pressure, which is reflected back at the heart during that heart-beat. This combined pressure, the pressure the heart pumps against, is increased by arterial stiffening and can be reduced with lifestyle changes and drug therapies.

About AtCor Medical

AtCor Medical develops and markets products for the early detection and management of cardiovascular disease. More than 1,200 SphygmoCor systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com

Contact Information

  • Contacts:

    Investor Relations
    Rachel Levine
    T: 646-284-9439
    E: rlevine@hfgcg.com

    Media Relations
    Ivette Almeida
    T: 646-284-9455
    E: ialmeida@hfg